AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$BBNX

Feider Stephen sold $128K of BBNX

Feider Stephen (Chief Financial Officer) sold 6,675 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.13M total) on 2026-09-02.

Original reporting
SEC EDGAR · Feider Stephen
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Neutral
high confidence
Mentioned
$BBNX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock, but it adds to the public record of insider activity.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming FDA decisions or product milestones could outweigh the impact of this small sale.

Relevance 4/10Novelty 4/10Timing: filed Sep 3, 2026

Background

Beta Bionics, a developer of implantable artificial pancreas devices, filed a Form 4 reporting an insider sale.

Company-level read

Ticker impact

$BBNXNeutralHigh confidence
Context

CFO Stephen Feider sold 6,675 shares for $127,580, reducing his stake to 159,378 shares.

Expected impact

Limited impact; price likely unchanged unless cumulative insider sales increase.

Evidence & confidence

The transaction is a routine Form 4 filing with modest dollar amount; markets typically view such small sales as non-material.

Market effects

Sector

No significant effect on the medical device sector.

Regional

Limited to US investors tracking Beta Bionics.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

If insiders are reducing positions, it could hint at upcoming challenges not yet reflected in the stock.

Key entities

  • Company
    Beta Bionics, Inc.

    US-listed medical device company (ticker BBNX).

  • Executive
    Stephen Feider

    Chief Financial Officer of Beta Bionics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBNX insider trading history →

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min